FDA Priority Review Costs Remain Stable While Voucher Fee Ticks Up
Executive Summary
Formula was changed to better calculate the cost of a priority review, FDA says.
You may also be interested in...
Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee
Next fiscal year will be a good one to redeem a voucher, and probably to qualify for one as well.
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain
Even after paying BioMarin $67.5 million for the voucher itself, the firms still don’t know how much FDA will charge for a chance to get Praluent to market faster.